DDInter1269 DDInter1266
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Naproxen
Nateglinide {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Naproxen
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Fenoprofen
Fenoprofen {u} (Compound) resembles {v} (Compound) Naproxen
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) resembles Naproxen (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Naproxen (Compound)
Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Naproxen (Compound)
Nateglinide (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Naproxen (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Naproxen (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Nateglinide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ketoprofen (Compound) and Ketoprofen (Compound) resembles Naproxen (Compound)
Nateglinide (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Fenoprofen (Compound) and Fenoprofen (Compound) resembles Naproxen (Compound)